Frequently Asked Questions

Once safety and manufacturing protocols have been proven, the FDA will consider an approval when there is a reasonable expectation of effectiveness for use. The conditional approval is valid for one year, after which it must be renewed annually (for up to four additional years) by demonstrating progress toward full approval.

Yes.

Dogs receiving KBr should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance.

Please consult your veterinarian if seizure frequency increases. The total recommended daily dosage range for oral administration is 25–68 mg/kg (11–31 mg/lb) of body weight. The dosage of KBroVet should be adjusted based on monitoring of clinical response of the individual dog.

Yes, the tablets contain a proprietary flavoring to increase acceptance by dogs.

Store at controlled room temperature 20–25°C (68–77°F). Keep out of reach of children and animals. Additionally, clients should be advised to keep KBroVet in a secured location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

The two products are labeled differently due the FDA’s approval of KBroVet. Please see the full product label and package insert for details. Additionally, the tablets are no longer scored, nor contain cyanocobalamin (vitamin B-12). All other ingredients remain the same.

The most commonly reported side effects were increased appetite and thirst, increased urination, weight gain, sedation, and ataxia. For full prescribing information see the package insert by clicking here.

KBroVet should not be used in animals with a history of hypersensitivity to bromide. Please see full product label and package insert for all labeled contraindications, warning and precautions.